A spokesperson for Cambridge, Massachusetts-based Sarepta declined to comment on the lawsuit. A Sanofi spokesperson reiterated the allegations in the complaint.
DMD is a severe degenerative genetic disorder that primarily affects boys. The U.S. Food and Drug Administration approved Sarepta's Elevidys, the first gene therapy for DMD, last year and allowed the expanded use of the drug in June.
Sarepta earned more than $200 million from sales of Elevidys last year.
According to Reuters, Genzyme's lawsuit, filed on Friday, said that its scientists invented a "highly technical, multi-phase process" for manufacturing gene therapies that Sarepta mimics to make Elevidys. It asked the court for an unspecified amount of damages for Sarepta's alleged patent infringement.
Sarepta won the dismissal of a separate patent lawsuit over Elevidys from biotech company Regenxbio earlier this year.
The case is Genzyme Corp v. Sarepta Therapeutics Inc, U.S. District Court for the District of Delaware, No. 1:24-cv-00882
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd